- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01437787
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly
Primary Objective:
- To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance imaging (MRI) (or computed tomography scan in patients with contraindications for MRI).
Secondary Objectives:
- To evaluate the effect on Myelofibrosis (MF)-associated symptoms (key MF symptoms) as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary.
- To evaluate the Overall Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo.
- To evaluate the Progression Free Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo.
- To evaluate the durability of splenic response.
- To evaluate the safety of IMP.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The expected duration of a patient's treatment in this study is approximately 8 months, based on a maximum 28-day screening period, followed by a ≥6-month (6-cycle) treatment period, and an End Of Treatment (EOT) visit, which should be performed at least 30 days following the last administration of IMP or placebo.
Patients who continue to benefit clinically will be allowed to remain on IMP or placebo beyond the 6-month treatment period until the occurrence of disease progression or unacceptable toxicity.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Box Hill, Australia, 3128
- Investigational Site Number 036001
-
Herston, Australia, 4029
- Investigational Site Number 036005
-
Randwick, Australia, 2031
- Investigational Site Number 036003
-
Tweed Heads, Australia, 2485
- Investigational Site Number 036004
-
Wodonga, Australia, 3690
- Investigational Site Number 036002
-
-
-
-
-
Wien, Austria, 1090
- Investigational Site Number 040001
-
-
-
-
-
Antwerpen, Belgio, 2060
- Investigational Site Number 056003
-
Leuven, Belgio, 3000
- Investigational Site Number 056001
-
-
-
-
-
Jau, Brasile, 17210-120
- Investigational Site Number 076002
-
Porto Alegre, Brasile, 90110-270
- Investigational Site Number 076004
-
Rio De Janeiro, Brasile, 20230-130
- Investigational Site Number 076001
-
-
-
-
-
Montreal, Canada, H1T 2M4
- Investigational Site Number 124001
-
Montreal, Canada, H2W 1S6
- Investigational Site Number 124003
-
Saint John, Canada, E2L 4L2
- Investigational Site Number 124002
-
-
-
-
-
Bundang-Gu, Corea, Repubblica di, 463-707
- Investigational Site Number 410002
-
Seoul, Corea, Repubblica di, 110-744
- Investigational Site Number 410004
-
Seoul, Corea, Repubblica di, 135-710
- Investigational Site Number 410001
-
Seoul, Corea, Repubblica di, 120-752
- Investigational Site Number 410003
-
Seoul, Corea, Repubblica di, 137-701
- Investigational Site Number 410005
-
Seoul, Corea, Repubblica di, 138-878
- Investigational Site Number 410006
-
Seoul, Corea, Repubblica di
- Investigational Site Number 410007
-
-
-
-
-
Moscow, Federazione Russa, 125167
- Investigational Site Number 643009
-
Moscow, Federazione Russa, 125284
- Investigational Site Number 643001
-
Nizhny Novgorod, Federazione Russa, 603126
- Investigational Site Number 643010
-
Petrozavodsk, Federazione Russa, 185019
- Investigational Site Number 643008
-
St-Petersburg, Federazione Russa, 197341
- Investigational Site Number 643004
-
St.-Petersburg, Federazione Russa, 191024
- Investigational Site Number 643005
-
Volgograd, Federazione Russa, 400138
- Investigational Site Number 643007
-
-
-
-
-
Marseille, Francia, 13273
- Investigational Site Number 250006
-
Nantes Cedex 01, Francia, 44093
- Investigational Site Number 250005
-
Nimes, Francia, 30029
- Investigational Site Number 250004
-
Pierre Benite Cedex, Francia, 69495
- Investigational Site Number 250002
-
Poitiers, Francia, 86000
- Investigational Site Number 250007
-
Toulouse, Francia, 31000
- Investigational Site Number 250003
-
Villejuif Cedex, Francia, 94805
- Investigational Site Number 250001
-
-
-
-
-
Aachen, Germania, 52074
- Investigational Site Number 276006
-
Bonn, Germania, 53127
- Investigational Site Number 276007
-
Dresden, Germania, 01307
- Investigational Site Number 276008
-
Mannheim, Germania, 68167
- Investigational Site Number 276001
-
-
-
-
-
Dublin, Irlanda, DUBLIN 8
- Investigational Site Number 372002
-
Galway, Irlanda
- Investigational Site Number 372001
-
-
-
-
-
Haifa, Israele, 31048
- Investigational Site Number 376003
-
Tel Hashomer, Israele, 52621
- Investigational Site Number 376002
-
-
-
-
-
Bergamo, Italia, 24127
- Investigational Site Number 380002
-
Bologna, Italia, 40138
- Investigational Site Number 380007
-
Firenze, Italia, 50134
- Investigational Site Number 380004
-
Pavia, Italia, 27100
- Investigational Site Number 380001
-
Pavia, Italia, 27100
- Investigational Site Number 380006
-
Varese, Italia, 21100
- Investigational Site Number 380003
-
-
-
-
-
Kaunas, Lituania, LT-50009
- Investigational Site Number 440001
-
Klaipeda, Lituania, LT-92288
- Investigational Site Number 440002
-
-
-
-
-
Queretaro, Messico, 76000
- Investigational Site Number 484001
-
-
-
-
-
Brzozow, Polonia, 36-200
- Investigational Site Number 616005
-
Gdansk, Polonia, 80-952
- Investigational Site Number 616002
-
Lodz, Polonia, 93-510
- Investigational Site Number 616006
-
Warszawa, Polonia, 02-106
- Investigational Site Number 616010
-
Wroclaw, Polonia, 50-367
- Investigational Site Number 616003
-
-
-
-
-
Coimbra, Portogallo, 3000-075
- Investigational Site Number 620005
-
Lisboa, Portogallo, 1649-035
- Investigational Site Number 620001
-
Lisboa, Portogallo, 1169-050
- Investigational Site Number 620004
-
Porto, Portogallo, 4200-072
- Investigational Site Number 620003
-
-
-
-
-
Belfast, Regno Unito, BT9 7AB
- Investigational Site Number 826006
-
Birmingham, Regno Unito, B9 5SS
- Investigational Site Number 826003
-
Glasgow, Regno Unito, G12 0YN
- Investigational Site Number 826002
-
Leeds, Regno Unito, LS9 7TF
- Investigational Site Number 826004
-
London, Regno Unito, SE1 9RT
- Investigational Site Number 826001
-
London, Regno Unito, W12 0HS
- Investigational Site Number 826005
-
Manchester, Regno Unito, M20 4BX
- Investigational Site Number 826007
-
Newcastle Upon Tyne, Regno Unito, NE7 7DN
- Investigational Site Number 826008
-
Oxford, Regno Unito, OX3 7LJ
- Investigational Site Number 826009
-
Southampton, Regno Unito, SO16 6YD
- Investigational Site Number 826010
-
-
-
-
-
Brasov, Romania
- Investigational Site Number 642003
-
Bucharest, Romania, 022328
- Investigational Site Number 642004
-
Bucuresti, Romania, 030171
- Investigational Site Number 642002
-
Bucuresti, Romania
- Investigational Site Number 642006
-
Timisoara, Romania
- Investigational Site Number 642001
-
-
-
-
-
Singapore, Singapore, 119228
- Investigational Site Number 702002
-
Singapore, Singapore, 169608
- Investigational Site Number 702001
-
-
-
-
-
Barcelona, Spagna, 08036
- Investigational Site Number 724001
-
Madrid, Spagna, 28046
- Investigational Site Number 724002
-
-
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 85259-5499
- Investigational Site Number 840014
-
-
California
-
La Jolla, California, Stati Uniti, 92093
- Investigational Site Number 840001
-
La Jolla, California, Stati Uniti, 92093
- Investigational Site Number 840012
-
Los Angeles, California, Stati Uniti, 90033
- Investigational Site Number 840006
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70808
- Investigational Site Number 840013
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Investigational Site Number 840008
-
-
New Jersey
-
Newark, New Jersey, Stati Uniti, 07112
- Investigational Site Number 840009
-
-
Ohio
-
Canton, Ohio, Stati Uniti, 44718
- Investigational Site Number 840002
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Investigational Site Number 840004
-
-
-
-
-
Johannesburg, Sud Africa, 2013
- Investigational Site Number 710003
-
Parktown, Sud Africa, 2193
- Investigational Site Number 710002
-
-
-
-
-
Stockholm, Svezia, 14186
- Investigational Site Number 752001
-
Uddevalla, Svezia, 451 80
- Investigational Site Number 752002
-
-
-
-
-
Changhua, Taiwan, 500
- Investigational Site Number 158002
-
Kaohsiung, Taiwan, 833
- Investigational Site Number 158003
-
Taipei, Taiwan, 112
- Investigational Site Number 158001
-
-
-
-
-
Budapest, Ungheria, 1097
- Investigational Site Number 348002
-
Debrecen, Ungheria, 4032
- Investigational Site Number 348001
-
Györ, Ungheria, 9023
- Investigational Site Number 348007
-
Kecskemét, Ungheria, 6000
- Investigational Site Number 348006
-
Miskolc, Ungheria, 3529
- Investigational Site Number 348003
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria:
- Diagnosis of Primary Myelofibrosis (MF) or Post-Polycythemia Vera MF or Post-Essential Thrombocythemia MF, according to the 2008 World Health Organization and International Working Group of Myelofibrosis Research and Treatment (IWG-MRT) criteria.
- MF classified as high-risk or intermediate-risk level 2, as defined by modified IWG-MRT criteria (IPSS) (according to Cervantes F. et. al.; at screening).
- Enlarged spleen, palpable at least 5 cm below costal margin.
- At least 18 years of age.
- Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at study entry.
- The following laboratory values within 14 days prior to the initiation of IMP or placebo:
- Absolute Neutrophil Count (ANC) ≥1.0 x 10exp9/L
- Platelet count ≥50 x 10exp9/L
- Serum creatinine ≤1.5 x Upper Limit of Normal (ULN)
- Serum amylase and lipase ≤1.5 x ULN
Exclusion criteria:
- Splenectomy.
- Any chemotherapy (eg, hydroxyurea), immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), Anagrelide, immunosuppressive therapy, corticosteroids >10 mg/day prednisone or equivalent, or growth factor treatment (eg, erythropoietin), or hormones (eg, androgens, danazol) within 14 days prior to initiation of IMP or placebo; darbepoetin use within 28 days prior to initiation of IMP or placebo. Patients who have had exposure to hydroxyurea (eg, hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to initiation of IMP or placebo.
- Major surgery within 28 days or radiation within 6 months prior to initiation of IMP or placebo.
- Prior treatment with a Janus Kinase 2 (JAK2) inhibitor.
- Known active (acute or chronic) Hepatitis A, B, or C; and hepatitis B and C carriers
- AST or ALT ≥2.5 x ULN
- Total Bilirubin:
- Exclude if ≥3.0 x ULN
- Patients with total bilirubin between 1.5-3.0 x ULN must be excluded if the direct bilirubin fraction is ≥25% of the total
- Prior history of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH])
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore placebo: Placebo comparator
once daily X 28 days, orally, empty stomach, approximately same time each day
|
Pharmaceutical form:capsule Route of administration: oral |
Sperimentale: SAR302503 400 mg
once daily X 28 days, orally, empty stomach, approximately same time each day
|
Forma farmaceutica: capsula Via di somministrazione: orale |
Sperimentale: SAR302503 500 mg
once daily X 28 days, orally, empty stomach, approximately same time each day
|
Forma farmaceutica: capsula Via di somministrazione: orale |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Response Rate (RR), defined as the proportion of patients who have a ≥35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter
Lasso di tempo: 6 months
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Symptom Response Rate (SRR): Proportion of patients with ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score.
Lasso di tempo: 6 months
|
This assessment will be conducted through the modified MFSAF diary, which will be completed during the week prior to Day 1 of each treatment cycle up to Cycle 6, and during the week prior to the end of Cycle 6.
|
6 months
|
OS (overall survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.
Lasso di tempo: approximately 5 years
|
approximately 5 years
|
|
PFS (progression free survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.
Lasso di tempo: approximately 5 years
|
approximately 5 years
|
|
Proportion of patients who have ≥25% reduction in volume of spleen size at end of Cycle 6, and confirmed 4 weeks thereafter.
Lasso di tempo: 6 months
|
6 months
|
|
Duration of spleen response, measured by MRI (or CT scan in patients with contraindications for MRI.
Lasso di tempo: 2 years
|
2 years
|
|
Clinical and laboratory events graded by the NCI CTCAE v4.03.
Lasso di tempo: approximately 5 years
|
approximately 5 years
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EFC12153
- 2011-001897-25 (Numero EudraCT)
- U1111-1121-7170 (Altro identificatore: UTN)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su SAR302503
-
SanofiCompletatoNeoplasia ematopoieticaStati Uniti, Austria, Belgio, Canada, Francia, Germania, Italia, Olanda, Spagna, Regno Unito
-
SanofiCompletato
-
SanofiCompletatoInsufficienza renaleStati Uniti
-
SanofiCompletatoInsufficienza epaticaStati Uniti
-
SanofiCompletatoNeoplasia malignaBelgio, Stati Uniti
-
SanofiCompletato
-
SanofiCompletatoNeoplasia ematopoieticaStati Uniti, Spagna, Francia, Canada, Australia, Corea, Repubblica di, Germania, Italia, Regno Unito
-
University of WashingtonReclutamentoLeucemia mieloide acuta | Mielofibrosi primaria | Policitemia vera | Trombocitemia essenziale | Sindrome mielodisplasica | Neoplasia mieloproliferativa | Neoplasia mielodisplastica/mieloproliferativa | Mielofibrosi secondaria | Neoplasia mieloproliferativa, non classificabileStati Uniti
-
SanofiCompletatoTumore solidoStati Uniti